Dopamine transporter loss and clinical changes in MPTP-lesioned primates

Brain Research

Volumn 832, Issue 1-2, 1999, Pages 184-187

  Eberling, Jamie L ^a   Bankiewicz, Krzysztof S ^b   Pivirotto, Phillip ^c   Bringas, John ^c   Chen, Karen ^c   Nowotnik, David P ^d   Steiner, Joseph P ^d   Budinger, Thomas F ^a   Jagust, William J ^a,e  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c CroMedica Biosciences   (United States)

^d GUILFORD PHARMACEUTICALS INC   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CIT; Dopamine transporter; Monkey; MPTP; Parkinson's disease; Single photon emission computed tomography

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 BETA CARBOXYMETHOXY 3 BETA (4 IODOPHENYL)TROPANE; DOPAMINE TRANSPORTER; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; MACACA; NERVE DEGENERATION; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CARRIER PROTEINS; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MPTP POISONING; NERVE TISSUE PROTEINS; PARKINSON DISEASE, SECONDARY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033583936     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01491-2     Document Type: Article

References (25)

1. 3H ]paroxetine binding to serotonin uptake sites in human brain tissue Brain Res. 486:1989;261-268.
2. Bankiewicz K.S., Oldield E.H., Chiueh C.C., Doppman D.M., Jacobowitz D.M., Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39:1986;7-16.
3. 125I ]RTI-55: a potent ligand for dopamine transporters Eur. J. Pharmacol. 194:1991;133-134.
4. 123I ]beta-CIT. Binding kinetics in the human brain J. Neural Transm. Gen. Sect. 94:1993;137-146.
5. Eberling J.L., Jagust W.J., Taylor S., Bringas J., Pivirotto P., VanBrocklin H.F., Bankiewicz K.S. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. Brain Res. 805:1998;259-262.
6. 123I ]CIT Eur J. Pharmacol. 200:1991;369-370.
7. Ishikawa T., Dhawan V., Kazumata K., Chaly T., Mandel F., Neumeyer J., Margouleff C., Babchyck B., Zanzi I., Eidelberg D. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET. J. Nucl. Med. 37:1996;1760-1765.
8. 18F ]fluoro-L-m-tyrosine: metabolism, PET kinetics, and MPTP lesions in primates Brain Res. 750:1997;264-276.
9. 125I ]RTI-55 Synapse. 12:1992;99-111.
10. Kaufman M.J., Madras B.K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 9:1991;43-49.
11. 123I ]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates Synapse. 13:1993;295-309.
12. 3H ]paroxetine binding, a marker of serotonin uptake sites Biol. Psychiatry. 24:1988;299-309.
13. 123I ]β-CIT binding to dopamine transporters in healthy human subjects J. Cereb. Blood Flow Metab. 14:1994;982-994.
14. Leenders K.L., Palmer A.J., Quinn N., Clark J.C., Firnau G., Garnett E.S., Nahmias C., Jones T., Marsden C.D. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J. Neurol. Neurosurg. Psychiatry. 49:1986;853-860.
15. 123I ] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease Neurology. 46:1996;231-237.
16. 18F ]fluoro-L-m-tyrosine: an 1-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography J. Neurochem. 53:1989;311-314.
17. 123I ]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients Eur. Neurol. 39:1998;44-48.
18. 18F ]6-fluoro-L-m-tyrosine in the human brain Mov. Disord. 10:1995;298-304.
19. 123I ]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain J. Med. Chem. 34:1991;3144-3146.
20. 123I ]β-CIT SPECT Parkinsonism and Related Disorders. 1:1995;47-51.
21. 123I ]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease Ann. Neurol. 38:1995;589-598.
22. Shaya E.K., Scheffel U., Dannals R.F., Ricaurte G.A., Carroll F.I., Wagner H.N.J., Kuhar M.J., Wong D.F. In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse. 10:1992;169-172.
23. Szabo J., Cowan W.M. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. Comp. Neurol. 222:1984;265-300.
24. 123I ]beta-CIT SPECT J. Neurol. 245:1998;14-20.
25. 123I ] beta-CIT binding with SPECT in controls, early and late Parkinson's disease Nucl. Med. Biol. 22:1995;985-991.